Mineralys Therapeutics
MLYS
106 hedge funds and large institutions have $540M invested in Mineralys Therapeutics in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
65% more call options, than puts
Call options by funds: $109K | Put options by funds: $66K
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
13% more funds holding
Funds holding: 94 → 106 (+12)
5% more capital invested
Capital invested by funds: $517M → $540M (+$23.5M)
0.32% more ownership
Funds ownership: 88.92% → 89.25% (+0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$8.52M |
| 2 |
IHAM
Integral Health Asset Management
New York
|
+$4.31M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$3.18M |
| 4 |
CP
Caligan Partners
New York
|
+$2.85M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$8.65M |
| 2 |
CP
Catalys Pacific
Tokyo,
Japan
|
-$6.66M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.43M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$3.21M |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BF
101
BOK Financial
Tulsa,
Oklahoma
| $323 | +$303 | +25 | New |
|
|
CPA
102
Capital Performance Advisors
Walnut Creek,
California
| $279 | +$278 | +23 | New |
|
|
PA
103
Parallel Advisors
San Francisco,
California
| $266 | – | – | – |
|
|
FFA
104
Farther Finance Advisors
San Francisco,
California
| $206 | – | – | – |
|
105
Nisa Investment Advisors
St. Louis,
Missouri
| $61 | -$738 | -61 | -92% |
|
|
RSCM
106
Rock Springs Capital Management
Baltimore,
Maryland
| – | -$4.43M | -378,932 | Closed |
|
|
ECM
107
ExodusPoint Capital Management
New York
| – | -$3.21M | -274,316 | Closed |
|
|
DCM
108
Driehaus Capital Management
Chicago,
Illinois
| – | -$3.01M | -257,371 | Closed |
|
109
Two Sigma Investments
New York
| – | -$189K | -16,134 | Closed |
|
|
EC
110
EntryPoint Capital
New York
| – | -$93.1K | -7,956 | Closed |
|
111
Osaic Holdings
Scottsdale,
Arizona
| – | -$1.17K | -100 | Closed |
|
MLYS Hedge Fund Activity: Q3 2024 in Review
106 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q3 2024, worth a combined $540M — up 4.5% from $517M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new MLYS positions and 6 closed out — a net gain of 12 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was ADAR1 Capital Management, adding an estimated $8.52M. The largest seller was TCG Crossover Management, cutting an estimated $8.65M.
- 106 institutional investors held Mineralys Therapeutics (MLYS) as of Q3 2024, up from 94 in Q2 2024.
- Funds reported $540M of Mineralys Therapeutics stock for Q3 2024, up 4.5% quarter-over-quarter.
- 18 funds opened new Mineralys Therapeutics positions in Q3 2024 and 6 closed out, a net change of +12 holders.
- The largest Mineralys Therapeutics buyer in Q3 2024 was ADAR1 Capital Management, an estimated $8.52M added.
- The largest Mineralys Therapeutics seller in Q3 2024 was TCG Crossover Management, an estimated $8.65M sold.
Based on aggregated 13F filings for Q3 2024.